The receptor CDCP1 is emerging as a target for theranostics and ADCs for multiple cancers including ovarian cancer, PDAC and castration resistant prostate cancer including PSMA null disease 12-15, 26, 27. The gene discussed is CDCP1; the disease is prostate carcinoma.